Yatiri Bio Accurately Predicts AML Drug Response in Blinded Study Using Foghorn’s FHD-286SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- A demonstrated 100% concordance between biomarker-guided predictions from pre-treatment patient samples and clinical outcomes validates Yatiri Bio’s platform as a breakthrough in oncology patient stratification.
Yatiri Bio Receives Grant to Advance Proteomics Interoperability in Cancer ResearchSAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Yatiri Bio Inc. today announced it has received a grant from the Gates Foundation to launch a one-year project, Proteomics Interoperability, aimed at improving how large-scale proteomics data can be integrated and applied to global health challenges.
Yatiri Bio Acquires NGeneBioAI to Expand AI-Powered Proteomics Platform and Advance Precision Biomarker DiscoverySAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Yatiri Bio, Inc., a leader in proteomics-driven precision medicine, today announced the successful acquisition of NGeneBioAI, Inc., a San Diego-based company specializing in plasma proteomics and AI-powered diagnostics. The acquisition strengthens Yatiri Bio’s position at the forefront of biomarker discovery and translational drug development.
